Retinopathy Of Prematurity - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Retinopathy Of Prematurity - Pipeline Review, H1 2015', provides an overview of the Retinopathy Of Prematurity's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Retinopathy Of Prematurity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinopathy Of Prematurity and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Retinopathy Of Prematurity - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Retinopathy Of Prematurity and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Retinopathy Of Prematurity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Retinopathy Of Prematurity pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Retinopathy Of Prematurity - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Retinopathy Of Prematurity pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Retinopathy Of Prematurity Overview 6 Therapeutics Development 7 Pipeline Products for Retinopathy Of Prematurity - Overview 7 Pipeline Products for Retinopathy Of Prematurity - Comparative Analysis 8 Retinopathy Of Prematurity - Therapeutics under Development by Companies 9 Retinopathy Of Prematurity - Pipeline Products Glance 10 Clinical Stage Products 10 Early Stage Products 11 Retinopathy Of Prematurity - Products under Development by Companies 12 Retinopathy Of Prematurity - Companies Involved in Therapeutics Development 13 Acucela Inc. 13 Biomar Microbial Technologies 14 EyeGene, Inc. 15 F. Hoffmann-La Roche Ltd. 16 Gene Signal International SA 17 Insmed Incorporated 18 Retinopathy Of Prematurity - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 aganirsen - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 EG-Mirotin - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 emixustat hydrochloride - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 IB-09A0133 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 mecasermin rinfabate - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 R-200 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 ranibizumab - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Small Molecule for Retinopathy of Prematurity - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Retinopathy Of Prematurity - Recent Pipeline Updates 42 Retinopathy Of Prematurity - Product Development Milestones 49 Featured News & Press Releases 49 Apr 29, 2008: Acucela Presents Preclinical Data From Retinopathy Study Demonstrating Improvement In Retinal Abnormalities 49 Appendix 50 Methodology 50 Coverage 50 Secondary Research 50 Primary Research 50 Expert Panel Validation 50 Contact Us 50 Disclaimer 51
List of Tables Number of Products under Development for Retinopathy Of Prematurity, H1 2015 7 Number of Products under Development for Retinopathy Of Prematurity - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Comparative Analysis by Clinical Stage Development, H1 2015 10 Comparative Analysis by Early Stage Development, H1 2015 11 Products under Development by Companies, H1 2015 12 Retinopathy Of Prematurity - Pipeline by Acucela Inc., H1 2015 13 Retinopathy Of Prematurity - Pipeline by Biomar Microbial Technologies, H1 2015 14 Retinopathy Of Prematurity - Pipeline by EyeGene, Inc., H1 2015 15 Retinopathy Of Prematurity - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 16 Retinopathy Of Prematurity - Pipeline by Gene Signal International SA, H1 2015 17 Retinopathy Of Prematurity - Pipeline by Insmed Incorporated, H1 2015 18 Assessment by Monotherapy Products, H1 2015 19 Number of Products by Stage and Target, H1 2015 21 Number of Products by Stage and Mechanism of Action, H1 2015 23 Number of Products by Stage and Route of Administration, H1 2015 25 Number of Products by Stage and Molecule Type, H1 2015 27 Retinopathy Of Prematurity Therapeutics - Recent Pipeline Updates, H1 2015 42
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.